The World Health Organization (WHO) has issued revised guidelines for the treatment of Multi-system Inflammatory Syndrome in Children Caused by COVID-19 (MIS-C).
On Tuesday, WHO announced this on its website, stating that MIS-C was a rare but serious condition in which children with COVID-19 developed inflammation affecting various organs of the body.
“Children with this condition require specialized care and may require admission to intensive care.”
“Although MIS-C is a serious condition, children with this condition recover with the right medical care,” it said.
It was also stated that the World Health Organization’s updated guidelines recommended the use of corticosteroids in hospitalized children (aged 0-18 years) with this condition in addition to supportive treatment and care.
Corticosteroids are a type of medication that is used to reduce body inflammation.
This recommendation is based on the availability of three observational studies, which pooled data from a total of 885 patients, according to the statement.
“In May 2020, the World Health Organization (WHO) first described this condition and provided a preliminary clinical definition.”
“Overall, children continue to have a low risk of developing severe or critical COVID-19, but, as with adults, certain underlying conditions make children more susceptible to severe disease,” the study concluded.
Obesity, chronic lung disease (including asthma), cardiovascular disease, and immunosuppression were among the most commonly reported conditions, according to the statement.
Discussion about this post